Bio-Path Holdings, Inc. (BPTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
BPTH Stock Price Chart Interactive Chart >
BPTH Price/Volume Stats
| Current price | $3.90 | 52-week high | $8.62 |
| Prev. close | $3.87 | 52-week low | $2.68 |
| Day low | $3.89 | Volume | 478 |
| Day high | $3.90 | Avg. volume | 54,701 |
| 50-day MA | $3.35 | Dividend yield | N/A |
| 200-day MA | $3.97 | Market Cap | 27.92M |
Bio-Path Holdings, Inc. (BPTH) Company Bio
Bio-Path Holdings, Inc. focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. The company was founded in 2007 and is based in Bellaire, Texas.
Latest BPTH News From Around the Web
Below are the latest news stories about Bio-Path Holdings Inc that investors may wish to consider to help them evaluate BPTH as an investment opportunity.
Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual ConferenceHOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET. An audio webcast of the pr |
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual MeetingPreliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML PatientsHOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces a poster highlighting the safety and preliminary efficacy data of its Phase 2 study of prexigebersen (BP1001) was presented at the 2021 American So |
Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
Brokerages Anticipate Bio-Path Holdings, Inc. (NASDAQ:BPTH) to Announce -$0.32 EPSAnalysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to post earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Paths earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.35). Bio-Path posted earnings of ($0.57) per share during the same quarter last year, [] |
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q3 2021 Results - Earnings Call TranscriptNo summary available. |
BPTH Price Returns
| 1-mo | 15.04% |
| 3-mo | 1.04% |
| 6-mo | 3.45% |
| 1-year | -40.46% |
| 3-year | -73.32% |
| 5-year | -95.00% |
| YTD | 3.45% |
| 2021 | 7.71% |
| 2020 | -56.20% |
| 2019 | 128.29% |
| 2018 | -91.25% |
| 2017 | -85.19% |
Loading social stream, please wait...